Log in to your Inderes Free account to see all free content on this page.
Lundbeck
44
DKK
-0.32 %
HLUN B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
5 following
-0.32%
-2.61%
-8.33%
+18.79%
+34.31%
+33.09%
+38.67%
-13.83%
+78.86%
www.lundbeck.com/global
Lundbeck is a pharmaceutical company. The greatest focus is found in research on psychiatric and neurotic disorders, which includes the treatment of depression, schizophrenia, Alzheimer's and Parkinson's syndrome. The company conducts research, development and distribution of medicines where the customer base can be found on a global level. The company was originally founded in 1915 and has its headquarters in Valby.
Revenue
19.91B
EBIT %
16.05 %
P/E
19.05
Dividend yield-%
1.59 %
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
HLUN B
Daily low / high price
43.78 / 44.14
DKK
Market cap
43.81B DKK
Turnover
1.14M DKK
Volume
26K
Financial calendar
Annual report
05.02.2025
General meeting
26.03.2025
Interim report
14.05.2025
Interim report
20.08.2025
Interim report
12.11.2025
ShowingAll content types
H. Lundbeck A/S: Lundbeck completes acquisition of Longboard
H. Lundbeck A/S: Lundbeck announces expiration of Longboard tender offer and that all tender offer conditions are fulfilled
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio